<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599922</url>
  </required_header>
  <id_info>
    <org_study_id>AGTC_CNGB3-001</org_study_id>
    <secondary_id>R24EY022023</secondary_id>
    <nct_id>NCT02599922</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia</brief_title>
  <official_title>A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Genetic Technologies Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Applied Genetic Technologies Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of
      rAAV2tYF-PR1.7-hCNGB3 administered to one eye by subretinal injection in individuals with
      achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be
      safety and the secondary study endpoint will be efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of
      rAAV2tYF-PR1.7-hCNGB3 administered to one eye by subretinal injection in individuals with
      achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be
      safety and the secondary study endpoint will be efficacy.

      Subjects will be enrolled sequentially in four groups. Subjects in Groups 1, 2 and 3 will be
      at least 18 years of age and will receive a lower, middle or higher dose of study agent.
      Subjects in Group 4 will be at least 6 years of age and will receive the maximum tolerated
      dose identified in Groups 1, 2 and 3.

      Safety will be monitored by evaluation of ocular and non ocular adverse events and hematology
      and clinical chemistry parameters. Efficacy parameters will include visual acuity, light
      discomfort testing, color vision, static visual field, ERG, adaptive optics retinal imaging
      and OCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of participants experiencing grade 3 or greater adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in best corrected visual acuity compared to pre-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light aversion</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in light discomfort testing compared to pre-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color vision</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in color vision testing compared to pre-treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Achromatopsia</condition>
  <arm_group>
    <arm_group_label>Lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAAV2tYF-PR1/7-hCNGB3 will be administered at the lowest of three planned dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAAV2tYF-PR1/7-hCNGB3 will be administered at the middle of three planned dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAAV2tYF-PR1/7-hCNGB3 will be administered at the highest of three planned dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maximum tolerated dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAAV2tYF-PR1/7-hCNGB3 will be administered at the maximum tolerated dose identified from Groups 1, 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAAV2tYF-PR1.7-hCNGB3</intervention_name>
    <description>rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.</description>
    <arm_group_label>Lower dose</arm_group_label>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_label>Higher dose</arm_group_label>
    <arm_group_label>Maximum tolerated dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          1. Retinal disease consistent with a diagnosis of achromatopsia and documented mutations
             in both alleles of the CNGB3 gene;

          2. At least 18 years of age for Groups 1, 2 and 3 and at least 6 years of age for Group
             4;

          3. Able to perform tests of visual and retinal function;

          4. Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent
             20/80) based on the average of two examinations at the baseline visit;

          5. Acceptable laboratory parameters;

          6. For females of childbearing potential: A negative pregnancy test within 2 days before
             administration of study agent.

        Exclusion Criteria include:

          1. Refractive error of ≥ -8.00 diopters (spherical equivalent) of myopia in the study
             eye;

          2. Evidence of degenerative myopia regardless of the refractive error in the study eye;

          3. Pre-existing eye conditions that would contribute to vision loss in either eye or
             increase the risk of subretinal injection in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Feinsod, MD</last_name>
    <role>Study Director</role>
    <affiliation>Applied Genetics Technologies Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Dolgin, PharmD</last_name>
    <email>advocacy@agtc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VitreoRetinal Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.agtc.com</url>
    <description>Sponsor website</description>
  </link>
  <reference>
    <citation>Komáromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A, Tanaka JC, Acland GM, Hauswirth WW, Aguirre GD. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010 Jul 1;19(13):2581-93. doi: 10.1093/hmg/ddq136. Epub 2010 Apr 8. Erratum in: Hum Mol Genet. 2011 Dec 15;20(24):5024.</citation>
    <PMID>20378608</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Color Vision Defects</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

